Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Therapeutics (Nasdaq: TPST) announced that its Compensation Committee has granted stock options to one employee under the company's 2023 Inducement Plan. The grant consists of nonqualified stock options to purchase 9,450 shares of common stock. The options will vest over a four-year period, with 25% vesting on the first employment anniversary and the remaining 1/48th vesting monthly thereafter, contingent on continued employment.
Tempest Therapeutics (Nasdaq: TPST) ha annunciato che il suo Comitato per le Compensazioni ha concesso opzioni azionarie a un dipendente nell'ambito del Piano di Induzione 2023 dell'azienda. La concessione consiste in opzioni azionarie non qualificate per acquistare 9.450 azioni ordinarie. Le opzioni si matureranno nell'arco di un periodo di quattro anni, con il 25% che matura al primo anniversario di assunzione e il rimanente 1/48 che matura mensilmente da quel momento in poi, a condizione di un impiego continuato.
Tempest Therapeutics (Nasdaq: TPST) anunció que su Comité de Compensación ha otorgado opciones de acciones a un empleado bajo el Plan de Inducción 2023 de la compañía. La concesión consiste en opciones de acciones no calificadas para comprar 9,450 acciones ordinarias. Las opciones se irán consolidando a lo largo de un período de cuatro años, con el 25% consolidándose en el primer aniversario del empleo y el restante 1/48 consolidándose mensualmente a partir de entonces, condicionado a un empleo continuo.
Tempest Therapeutics (Nasdaq: TPST)는 회사의 2023 유도 계획에 따라 한 직원에게 주식 옵션을 부여했다고 발표했습니다. 부여된 옵션은 9,450주의 보통주를 구매할 수 있는 비정치적 주식 옵션으로 구성되어 있습니다. 이 옵션은 4년 기간에 걸쳐 분할될 것이며, 최초 고용 기념일에 25%가 분할되고, 이후 매달 1/48이 분할되며, 지속적인 고용이 조건입니다.
Tempest Therapeutics (Nasdaq: TPST) a annoncé que son Comité de Rémunération a accordé des options d'actions à un employé dans le cadre du Plan d'Induction 2023 de l'entreprise. L'attribution se compose d'options d'actions non qualifiées pour acheter 9 450 actions ordinaires. Les options seront acquises sur une période de quatre ans, avec 25 % acquérant leurs droits lors du premier anniversaire de l'emploi et le reste 1/48 acquérant mensuellement par la suite, contingent à un emploi continu.
Tempest Therapeutics (Nasdaq: TPST) hat bekannt gegeben, dass der Vergütungsausschuss Aktienoptionen an einen Mitarbeiter im Rahmen des Unternehmensplans zur Anwerbung 2023 gewährt hat. Die Gewährung besteht aus nicht qualifizierten Aktienoptionen zum Kauf von 9.450 Aktien der Stammaktien. Die Optionen werden über einen Zeitraum von vier Jahren vestiert, wobei 25% nach dem ersten Beschäftigungsjubiläum vestieren und die verbleibenden 1/48 monatlich danach, abhängig von der fortgesetzten Beschäftigung.
- None.
- None.
BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 9,450 shares of its common stock under the Company’s 2023 Inducement Plan.
The stock options will vest over a four-year period, with
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Investor & Media Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
1 If approved by the FDA
FAQ
How many shares were granted in Tempest Therapeutics (TPST) December 2023 inducement grant?
What is the vesting schedule for TPST's December 2023 inducement stock options?
Under which plan did TPST issue its December 2023 stock options?
